Who
Rhonda Farnum
SVP, Comm & Medical Affairs
Company insider
Files Form 4 as: SVP, Comm & Medical Affairs, Theravance Biopharma.
In numbers
- Trades disclosed
- 71
- Buys
- 0
- Sells
- 17
- Bought
- $0
- Sold
- $3.0M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 14 Dec 2021
- Last trade
- 23 Sep 2026
- Last filed
- 24 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —124,414 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —89,062 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —150,000 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —150,000 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —124,414 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —89,062 | filing |
| 15 Sep 2026filed 17 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Sold | $57K3,329 at $17.03 | filing |
| 15 Sep 2026filed 17 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Sold | $57K3,328 at $17.03 | filing |
| 15 Sep 2026filed 17 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Sold | $113K6,657 at $17.03 | filing |
| 15 Sep 2026filed 17 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Sold | $57K3,329 at $17.03 | filing |
| 15 Sep 2026filed 17 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Sold | $57K3,328 at $17.03 | filing |
| 15 Sep 2026filed 17 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Sold | $113K6,657 at $17.03 | filing |
| 20 Aug 2026filed 24 Aug 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $96K5,667 at $16.95 | filing |
| 20 Aug 2026filed 24 Aug 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $96K5,667 at $16.95 | filing |
| 15 Jun 2026filed 17 Jun 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Sold | $55K3,329 at $16.39 | filing |
| 15 Jun 2026filed 17 Jun 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Sold | $55K3,328 at $16.38 | filing |
| 15 Jun 2026filed 17 Jun 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Sold | $109K6,657 at $16.39 | filing |
| 15 Jun 2026filed 17 Jun 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Sold | $55K3,329 at $16.39 | filing |
| 15 Jun 2026filed 17 Jun 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Sold | $55K3,328 at $16.38 | filing |
| 15 Jun 2026filed 17 Jun 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Sold | $109K6,657 at $16.39 | filing |
News
No headline names them, or the companies they trade most, lately.